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Introduction: While a positive margin after an attempt at breast conservation therapy (BCT) is a reason for concern, there is more controversy
regarding close margins. When re-excisions are performed, there is often no residual disease in the new specimen, calling into question the need
for the procedure. We sought to examine the incidence of residual disease after re-excision for close margins and to identify predictive factors that
may better select patients for re-excision.
Methods: Our IRB-approved prospective breast cancer database was queried for all breast cancer patients who underwent a re-excision
lumpectomy for either close or positive margins after an attempt at BCT. Close margins are defined as 2 mm for invasive carcinoma and 3 mm
for DCIS. Clinicopathologic features were correlated with the presence of residual disease in the re-excision specimen.
Results: Three hundred three patients (32%) underwent re-operation for either close (173) or positive (130) margins. Overall, 33% had residual
disease identified, 42% of DCIS patients and 29% of patients with invasive disease, nearly identical to patients with positive margins. For patients
with DCIS, only younger age was significantly related to residual disease. For patients with invasive cancer, only multifocality was significantly
associated with residual disease (OR 3.64 [1.26–10.48]). However, patients without multifocality still had a substantial risk of residual disease.
Discussion: The presence of residual disease appears equal between re-excisions for close and positive margins. No subset of patients with either
DCIS or invasive cancer could be identified with a substantially lower risk of residual disease.
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INTRODUCTION
While survival after breast conservation therapy (BCT) is
equivalent to mastectomy, the consequences of local recurrence are
not insignificant. Management of local recurrence can be both
physically and psychologically demanding for patients, and when
salvage mastectomy is necessary, one of the primary goals of breast
conserving therapy is thwarted. Furthermore, it is possible that
persistent local disease may seed (or reseed) distant metastases, with
potential impact upon overall survival. Indeed, the Oxford meta-
analysis has demonstrated a relationship between local control and
overall survival in breast cancer, concluding that for every four local
recurrences avoided by aggressive local therapy, a life may be saved
[1]. It is therefore incumbent upon breast surgeons and radiation
oncologists to optimize local control.
BCT consists of two components, lumpectomy and radiation
therapy. While the adjuvant radiation therapy is often considered
the most important factor for reducing local recurrence, the adequacy
of the lumpectomy is also important, specifically obtaining clear
microscopic margins. While a lumpectomy has clear advantages over
mastectomy, one disadvantage is the need sometimes to return to the
operating room for a re-excision lumpectomy. Re-excision rates are
high, ranging from 20% to 70% in the literature, and in addition to the
inconvenience and added costs, re-excision lumpectomies may result
in added complications and diminish the aesthetic outcome [2–13].
While the consensus is quite clear that patients with a positive
margin after lumpectomy require re-excision, there is more con-
troversy regarding the patient with close margins, including both
the definition of a close margin as well as the need to return to the
operating room versus proceeding with radiation [14]. Studies
examining whether local recurrence rates are increased when close
margins are not re-excised have been mixed [15–23]. When re-
excisions are performed, there is often no residual disease in the new
specimen, calling into question the need for the procedure.
At the University of Michigan, we have maintained a strict policy of
re-excision for close margins before proceeding with adjuvant
radiation. At our institution, a close margin is defined by our
pathologists as 2 mm for invasive cancer and 3 mm for ductal
carcinoma in situ (DCIS). This approach has resulted in a low rate of
local recurrence, but requires a higher rate of re-excisions [24,25]. We
therefore sought to examine the incidence of residual disease after re-
excision for close margins and to identify factors that may correlate
with residual disease in order to better select patients for re-excision.
MATERIALS AND METHODS
All biopsy-proven breast cancer patients seen at the University of
Michigan Comprehensive Cancer Center are presented at a multi-
disciplinary tumor board composed of surgical, medical, radiation
oncologists, radiologists, pathologists, and associated support staff.
Once a patient has undergone surgical management of this cancer at
the University of Michigan, data from these discussions and from the
patient treatment records are entered into a prospective breast cancer
database. For this study, our prospective breast cancer database was
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queried for all female patients with breast cancer who underwent a re-
excision lumpectomy for either close or positive margins after an initial
attempt at breast conservation surgery at the University of Michigan
between January 1, 2001 and December 31, 2005. Patients who
proceeded to adjuvant radiation with close or positive margins were
excluded. This study was approved by the Institutional Review Board
at the University of Michigan.
Close margins are defined at the University of Michigan as 2 mm
for invasive carcinoma and 3 mm for DCIS. The lumpectomy
specimen is routinely oriented for the pathologist using three marking
sutures and inked with six colors so that the involved margin can be
identified. For the purpose of this study, a re-excision lumpectomy is
defined as a second attempt to obtain negative margins. Therefore, a
lumpectomy performed after an excisional biopsy (without a diagnosis
of cancer) that had close or positive margins was not considered a re-
excision. Residual disease is defined as either DCIS or invasive cancer
identified within the re-excision specimen. Lobular carcinoma in
situ (LCIS), atypical ductal hyperplasia (ADH), or atypical lobular
hyperplasia (ALH) within the re-excision specimen were not con-
sidered residual disease. Fisher’s exact test was used to determine
significance between clinicopathologic features and the presence of
residual disease, with a P-value less than .05 deemed significant.
Multivariable analysis (MVA) was attempted for invasive cases using
standard logistic regression. Using a backward, stepwise selection
procedure, the most parsimonious model was constructed, retaining only
those covariates found to have Wald-type P-values less than or equal to
0.1. MVA was not attempted for DCIS, as the small sample could not
support multiple covariates. All statistical tests were conducted using
SAS software, Version 9.1 (SAS Institute, Inc., Cary, NC).
RESULTS
Over this time period, 948 women were deemed eligible for BCT
and had an initial attempt at a lumpectomy for either invasive breast
cancer or DCIS. Of these women, 303 (32%) underwent re-operation
for either close or positive margins. Positive margins prompted
re-excision in 173 patients (57%) while close margins prompted re-
operation in 130 patients (43%). This latter group comprises the
primary population for this study. The median age for this population
was 53.5 (range 31–88).
Thirty-one of the patients with close margins had DCIS, with or
without microinvasion (24 and 7, respectively). All but one was diagnosed
on screening mammography, with 28 having suspicious calcifications and
2 having a mass with calcifications. The final patient was discovered
incidentally and had a normal mammogram. The diagnosis was made
by image-guided core biopsy in 24 patients and excisional biopsy in
7 patients. Average tumor size was 1.0 cm (range 0.2–1.7 cm).
Ninety-nine of the patients with close margins had invasive cancer.
Fifty of these patients were diagnosed on screening mammography
while 34 discovered a mass on self-examination. Eight patients had a
mass discovered on clinical examination, three patients presented with
pain, and four patients initially presented with an axillary mass and
were found to harbor a breast cancer. Mammographic findings for
patients with invasive cancer included a mass in 69 patients (35 with
calcifications, 34 without), architectural distortion or focal density (8),
and calcifications alone (6). Three had missing data. Thirteen patients
had a normal mammogram. The diagnosis was made by an operative
biopsy in 22 patients and a percutaneous biopsy in 72 patients
(5 patients had missing data). Average tumor size was 1.5 cm (range
0.2–4.6 cm). Ductal histology was present in 83 patients (7 with
lobular features) and 10 patients had a lobular histology. The remaining
six patients had an apocrine (1), papillary (1), medullary (1), mucinous
(2), or metaplastic (1) histology.
Overall, 33% (43 patients) of those who returned for re-excision had
evidence of residual DCIS or invasive carcinoma identified. The
remaining 67% (87 patients) had no residual disease identified. For
both DCIS and invasive cancer, these numbers were remarkably similar
to the patients returning to the OR for positive margins (Fig. 1). For
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Fig. 1. Incidence of residual disease after re-excision for close or positive margins following lumpectomy for both DCIS and invasive cancer.
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patients with DCIS, residual disease was found in 45% of patients with
positive margins and 42% of patients with close margins. For patients
with invasive disease, residual disease was identified in 24% of patients
with positive margins and 29% of patients with close margins.
Risk factors predicting for residual disease upon re-excision were
analyzed separately for DCIS and invasive breast cancer cases.
Residual disease at the time of re-excision in patients with DCIS was
not significantly associated with a patient’s race, breast density on
mammogram, biopsy type, tumor size, nuclear grade, estrogen receptor
status, or presence of tumor necrosis (Table I). Residual disease was
significantly related to a patient’s age at surgery. Patients with residual
disease were on average significantly younger than patients without
residual disease (51.6 vs. 57.7 years, respectively).
Residual disease at re-excision for invasive disease was not
significantly associated with a patient’s race, age at surgery, clinical
presentation or mammographic findings, breast density on mammogra-
phy, biopsy type, T-stage/tumor size, positive node status, tumor
histology, nuclear grade, estrogen and progesterone receptor status,
HER2/Neu expression, lymphovascular invasion, or extensive intraductal
component of disease (Table II). However, residual disease was
significantly associated with multifocality. Patients with multifocal
disease were more likely to have residual disease upon re-excision. In
univariate analysis, the odds ratio estimated is 3.64 [95% CI 1.26–10.48],
indicating that patients with multifocality are over 3.5 times more likely
to have residual disease upon re-excision than patients without, although
the validity of this association can be challenged based upon the higher
proportion of missing data for this variable compared with others.
Multivariable analyses did not reveal any significant associations between
covariates and residual disease not first described on univariate analysis.
The most parsimonious model included solely multifocality, and hence
the model reduced to the univariate association already described.
Journal of Surgical Oncology





P-valueaYes N (%) No N (%)
Race
White 11 (42.3) 15 (57.7) 0.77
Black 1 (33.3) 2 (66.7)
Other 0 2 (100)
Age at surgery (years)
Mean 51.6 57.7 0.05b
Standard deviation 6.7 9.9
Breast density on mammogram
Not dense/mild 1 (33.3) 2 (66.7) 0.84
Moderate 6 (42.9) 8 (57.1)
Very 3 (60.0) 2 (40.0)
Unknown 2 (22.2) 7 (77.8)
Biopsy type 0.99
Percutaneous 9 (37.5) 15 (62.5)
Operative 3 (42.9) 4 (57.1)
Tumor size (cm)
Mean 1.17 0.95 0.41
Standard deviation 0.37 0.93
Nuclear grade
I 1 (33.3) 2 (66.7) 0.99
II 3 (42.9) 4 (57.1)
III 8 (40.0) 12 (60.0)
Unknown 0 1 (100)
Estrogen receptor
Positive 7 (38.9) 11 (61.1) 0.99
Negative 2 (40.0) 3 (60.0)
Unknown 3 (37.5) 5 (62.5)
Necrosis
Present 9 (37.5) 15 (62.5) 0.99
Absent 2 (33.3) 4 (66.7)
Unknown 1 (100) 0
aExcluding the unknown category if present.
bTwo-sample t-test using Satterthwaite’s approximation.





P-valueaYes N (%) No N (%)
Race
White 22 (26.5) 61 (73.5) 0.15
Black 4 (66.7) 2 (33.3)
Other 3 (30.0) 7 (70.0)
Age at surgery (years)
Mean 52.5 55.4 0.32b
Standard deviation 13.1 13.0
Breast density
Not dense/mild 4 (26.7) 11 (73.3) 0.99
Moderate 15 (30.0) 35 (70.0)
Very 1 (33.3) 2 (66.7)
Unknown 9 (29.0) 22 (71.0)
Biopsy type
Percutaneous 18 (25.0) 54 (75.0) 0.24
Operative 10 (45.5) 12 (54.5)
Other/unknown 1 (20.0) 4 (80.0)
Tumor size (cm)
Mean 1.67 1.42 0.30b
Standard deviation 1.20 0.74
Positive nodes
Yes 9 (25.0) 27 (75.0) 0.50
No 20 (32.3) 42 (67.7)
Unknown 0 1 (100)
Tumor histology
Ductal only 23 (30.3) 53 (69.7) 0.97
Ductal and lobular 2 (28.6) 5 (71.4)
Lobular only 3 (30.0) 7 (70.0)
Other 1 (16.7) 5 (83.3)
Nuclear grade
I 5 (31.3) 11 (68.7) 0.81
II 12 (25.0) 36 (75.0)
III 8 (30.8) 18 (69.2)
Unknown 4 (44.4) 5 (55.6)
Estrogen receptor
Positive 21 (29.6) 50 (70.4) 0.99
Negative 7 (26.9) 19 (73.1)
Unknown 1 (50.0) 1 (50.0)
Progesterone receptor
Positive 15 (28.9) 37 (71.1) 0.99
Negative 13 (28.9) 32 (71.1)
Unknown 1 (50.0) 1 (50.0)
Her2/Neu
Positive 5 (38.5) 8 (61.5) 0.52
Negative 23 (28.1) 59 (71.9)
Unknown 1 (25.0) 3 (75.0)
Multifocal disease
Yes 11 (52.4) 10 (47.6) 0.03
No 13 (23.2) 43 (76.8)
Unknown 5 (22.7) 17 (77.3)
Lymphovascular invasion
Present 5 (31.3) 11 (68.8) 0.99
Absent 22 (29.0) 54 (71.0)
Unknown 2 (28.6) 5 (71.4)
Extensive intraductal component
Present 7 (35.0) 13 (65.0) 0.59
Absent 20 (28.6) 50 (71.4)
Unknown 2 (22.2) 7 (77.8)
aExcluding the unknown category if present.
bTwo-sample t-test using Satterthwaite’s approximation.
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DISCUSSION
Although all breast surgeons would agree that the presence of
cancer extending to the inked margin after a lumpectomy is an
indication to return to the operating room, the same cannot be said
when the cancer approaches, but does not involve the margin. Some
have adopted a ‘‘negative is negative’’ approach, performing re-
excision lumpectomy only for positive margins. Among surgeons who
will re-excise for close margins, the definition of a close margin varies,
ranging anywhere from 1 to 4 mm. Even among the prospective
randomized trials that demonstrated the equivalency of BCT compared
with mastectomy, the definition of an ‘‘adequate lumpectomy’’ differed
between studies and in some cases was not specified.
To address this issue, several institutions have retrospectively
reviewed their experience with BCT, but these studies have failed to
answer this question definitively. In some series, the presence of close
margins was associated with an increased local recurrence rate
compared to widely negative margins [15,16,18–20]. Other studies,
however, failed to demonstrate this [21–23]. Interpretation of these
studies is further hampered by the fact that the technology behind
breast imaging and the delivery of radiation has consistently improved
over the past two decades, and by a selection bias in the decision to re-
excise or proceed with radiation therapy based on the location and size
(focal vs. broad) of the close margin. In addition, the assessment
of surgical margins is an inaccurate science as it is rarely feasible to
embed the entire margin of the lumpectomy in paraffin blocks
for analysis. Handling of the tissue, intraoperatively, ex vivo and
particularly during specimen mammography for wire-localized
lumpectomies, may compromise the margins, making clear margins
appear closer. Often a re-excision performed for either a close or even
positive margin fails to identify any residual disease, causing the
surgeon to question whether the procedure was necessary.
If it were possible to predict which patients reliably had no residual
disease in the specimen after undergoing re-excision, it might be
possible to selectively apply re-excision for close margins, thereby
decreasing re-excision rates and improving cosmetic outcomes without
compromising local recurrence rates. To examine this, we queried our
prospectively maintained database for patients who underwent a re-
excision lumpectomy for any close or positive margin after a definitive
lumpectomy, and assessed for the presence of residual disease.
Surprisingly, the likelihood of finding residual disease after re-excising
a close margin for either DCIS or invasive cancer was identical to the
presence of residual cancer after re-excising a positive margin. This
fact alone might suggest that there should be no difference in the
approach to either a close or positive margin.
We then sought to identify those patient or primary tumor features
that might correlate with the presence of residual disease, so as to
identify a group of patients for whom re-excision may be avoided. We
examined cases of DCIS and invasive cancer separately. For DCIS,
only age was significant, with younger patients more often having
residual disease (51.6 6.7 vs. 57.7 9.9, P¼ 0.48). The presentation,
mammographic appearance, and method of biopsy for patients with
DCIS were relatively uniform, precluding analysis. By Fisher’s exact
test, there was no significant correlation with the presence of residual
disease with breast density on mammography, type of biopsy, tumor
size, grade, ER expression, or presence of necrosis. It therefore seems
prudent to recommend that any patients, and especially younger
patients, with margins within 3 mm after lumpectomy for DCIS
undergo a re-excision lumpectomy.
Examining those patients with close margins after lumpectomy for
invasive cancer, there were several more factors that could be analyzed.
Surprisingly, neither histology (ductal vs. lobular) nor the method of
the initial biopsy (excisional vs. needle) correlated with the presence of
residual disease. On univariate and multivariate analysis, only
multifocality significantly correlated with the presence of residual
disease. More than half the patients with multifocality harbored
additional disease on re-excision, compared with less than a quarter of
the patients without multifocality. While this certainly suggests a
strong consideration for re-excision when multifocal disease is present,
it does not mean that the absence of multifocality precludes re-
excision, as over 20% of these patients still demonstrate additional
disease. As no other factor showed a significant association with
residual disease, a subset of patients without multifocality who can
avoid re-excision could not be identified. Therefore, re-excising close
margins after lumpectomy (2 mm) for invasive cancer must be
recommended.
Several caveats to this recommendation must be put forward. First,
a small selection bias is in play, as some patients with focally close
margins may have proceeded to radiation without re-excision based on
clinical scenario. As very few patients with close margins in our
database proceeded to radiation without re-excision, we are unable to
use this data to examine whether re-excision for close margins has any
impact on local recurrence. The presence of residual disease is not
necessarily a marker of an increased risk of recurrence and as we rarely
re-excise negative margins, there is no way to know the rate at which
identifiable residual disease goes unrecognized, something we know
does occur [26]. Although there were cases in our analysis where the
volume of residual disease was quite significant, and sometimes
prompted a second re-excision or mastectomy, in many cases the
residual disease consisted of small foci, less than 1 mm. It is possible
that this is the disease that is well managed by radiation therapy.
Recent data suggest this residual disease may be further controlled
through the use of a boost to the tumor bed. A large randomized trial
conducted by the EORTC has demonstrated a substantial decrease in
local recurrence rates among patients receiving a 16 Gy boost to the
tumor bed after whole breast irradiation of 50 Gy and microscopically
complete excision of early invasive breast cancer, as compared to
patients not receiving boost treatment [27]. More recently, preliminary
data presented from a central pathologic review of a subset of 1,724
patients with either completely resected tumors (treated on the
aforementioned trial with either a 16 Gy boost or no boost) or
incompletely resected disease (randomly assigned to 10 Gy vs. 26 Gy
boost in a separate section of the same study), have raised the
possibility that the radiation boost might compensate for inadequate
surgical margins [28]. Until these data have been peer-reviewed and
published, however, we continue to recommend re-excision to those
patients with close or positive margins in whom further resection is
technically feasible and likely to yield cosmetically acceptable results.
It should be noted that the 16 Gy boost treatment in the EORTC study
was associated with some detriment to cosmesis, with a significantly
higher 10-year cumulative incidence of moderate to severe breast
fibrosis among patients receiving the 16 Gy boost (28.1% with 66 Gy
vs. 13.2% with 50 Gy).
It is important in this context to point out that an aggressive use of
re-excision lumpectomy in patients with close margins does not result
in an excessively high number of re-excisions nor substantially
increase mastectomy rates (85% of patients with close margins in this
series still underwent successful BCT). Re-excision, when done
properly to assure negative margins but avoid excess breast tissue
removal, may still yield cosmetically acceptable results. This is
particularly true when the original specimen is properly oriented (e.g.,
short stitch superior, long stitch lateral, double stitch deep) so that the
pathologist can properly orient the specimen and ink the margins using
a 6-color system. This allows identification of the margin in question,
limiting re-excision to only that area [29].
In summary, in light of the fact that the presence of residual disease
appears equal between re-excisions for close margins and positive
margins, it seems difficult to justify not being equally aggressive in
both situations. As we could identify no subset of patients with a
substantially low enough risk of harboring additional disease for either
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patients with DCIS or invasive cancer, a selective approach to
re-excision does not appear justified. We continue to recommend re-
excision lumpectomy in all patients with margins 2 mm for invasive
ductal carcinoma and 3 mm for DCIS, with the exception of a highly
select group of patients, as agreed upon at a multidisciplinary breast
cancer tumor board.
REFERENCES
1. Clarke M, Collins R, Darby S, et al.: Effects of radiotherapy and
of differences in the extent of surgery for early breast cancer on
local recurrence and 15 year survival: An overview of the
randomized trials. Lancet 2005;366:2087–2106.
2. Cabioglu N, Hunt KK, Sahin AA, et al.: Role for intraoperative
margin assessment in patients undergoing breast-conserving
surgery. Ann Surg Oncol 2007;14:1458–1471.
3. Smitt MC, Horst K: Association of clinical and pathologic
variables with lumpectomy surgical margin status after preoper-
ative diagnosis or excisional biopsy of invasive breast cancer. Ann
Surg Oncol 2007;14:1040–1044.
4. Waljee JF, Hu ES, Newman LA, et al.: Predictors of re-excision
among women undergoing breast-conserving surgery for cancer.
Ann Surg Oncol 2008;15:1297–1303.
5. Cellini C, Hollenbeck ST, Christos PJ, et al.: Factors associated
with residual breast cancer after re-excision for close or positive
margins. Ann Surg Oncol 2004;11:915–920.
6. Keskek M, Kothari M, Ardehali B, et al.: Factors predisposing to
cavity margin positiviey following conservation surgery for breast
cancer. Eur J Surg Oncol 2004;30:1058–1064.
7. Jacobs L: Positive margins: The challenge continues for breast
surgeons. Ann Surg Oncol 2008;15:1271–1272.
8. Ramanah R, Pivot X, Sautiere JL, et al.: Predictors of re-excision
for positive or close margins in breast-conservation therapy for
pT1 tumors. Am J Surg 2008;195:770–774.
9. Gwin JL, Eisenberg BL, Hoffman JP, et al.: Incidence of gross and
microscopic carcinoma in specimens from patients with breast
cancer after re-excision lumpectomy. Ann Surg 1993;218:729–
734.
10. Kearney TJ, Morrow M: Effect of re-excision on the success of
breast-conserving surgery. Ann Surg Oncol 1995;2:303–307.
11. Papa MZ, Zippel D, Koller M, et al.: Positive margins of breast
biopsy: Is re-excision always necessary? J Surg Oncol 1999;70:
167–171.
12. Ratanawichitrasin A, Rybicki LA, Steiger E, et al.: Predicting the
likelihood of residual disease in women treated for ductal
carcinoma in situ. J Am Coll Surg 1999;188:17–21.
13. Miller AR, Brandao G, Prihoda TJ, et al.: Positive margins
following surgical resection of breast carcinoma: Analysis of
pathologic correlates. J Surg Oncol 2004;86:134–140.
14. Taghian A, Mohiuddin M, Jagsi R, et al.: Current perceptions
regarding surgical margin status after breast-conserving therapy:
Results of a survey. Ann Surg 2005;241:629–639.
15. Dewar JA, Arriagada R, Benhamou S, et al.: Local relapse and
contralateral tumor rates in patients with breast cancer treated
with conservative surgery and radiotherapy (institut Gustave-
Roussy 1970–1982). Cancer 1995;76:2260–2265.
16. Freedman G, Fowble B, Hanlon A, et al.: Patients with early-stage
invasive cancer with close or positive margins treated with
conservative surgery and radiation have an increased risk of breast
recurrence that is delayed by adjuvant systemic therapy. Int
J Radiat Oncol Biol Phys 1999;44:1005–1015.
17. Park C, Mitsumori M, Recht A, et al.: The relationship between
pathologic margin status and outcome after breast conserving
therapy. Int J Radiat Oncol Biol Phys 1998;42:125.
18. Anscher MS, Jones P, Prosnitz LR, et al.: Local failure and
margin status in early-stage breast carcinoma treated with
conservation surgery and radiation therapy. Ann Surg 1993;218:
22–228.
19. Smitt MC, Nowels K, Carlson RW, et al.: Predictors of re-excision
findings and recurrence after breast conservation. Int J Radiat
Oncol Biol Phys 2003;57:979–985.
20. Santiago RJ, Wu L, Harris E, et al.: Fifteen-year results of breast-
conserving surgery and definitive irradiation for stage I and II
breast carcinoma: The University of Pennsylvania experience. Int
J Radiat Oncol Biol Phys 2004;58:233–240.
21. Wazer DE, Schmidt-Ullrich RK, Ruthazer R, et al.: Factors
determining outcome for breast-conserving irradiation with
margin-directed dose escalation to the tumor bed. Int J Radiat
Oncol Biol Phys 1998;40:851–858.
22. Pittinger TP, Maronian NC, Poulter CA, et al.: Importance of
margins status in outcome of breast-conserving surgery for
carcinoma. Surgery 1994;116:605–608.
23. Obedian E, Haffty BG: Negative margin status improves local
control in conservatively managed breast cancer patients. Cancer
J Sci Am 2000;6:28–33.
24. Pierce LJ, Griffith KA, Hayman JA, et al.: Conservative surgery
and radiotherapy for stage I/II breast cancer using lung density
correction: 10-year and 15-year results. Int J Radiat Oncol Biol
Phys 2005;61:1317–1327.
25. Ben-David MA, Sturtz DE, Griffith KA, et al.: Long-term results
of conservative surgery and radiotherapy for ductal carcinoma in
situ using lung density correction: The University of Michigan
experience. Breast J 2007;13:392–400.
26. Holland R, Veling SH, Mravunac M, et al.: Histologic multi-
focality of Tis, T1-2 breast carcinomas. Implications for clinical
trials of breast-conserving surgery. Cancer 1985;56:979–990.
27. Bartelink H, Horiot JC, Poortmans PM, et al.: Impact of a higher
radiation dose on local control and survival in breast-conserving
therapy of early breast cancer: 10 year results of the randomized
boost versus no boost EORTC 2281-1088 trail. J Clin Oncol
2007;25:3259–3265.
28. Jones H, Antonini N, Colette L, et al.: The impact of boost dose
and margins on the local recurrence rate in breast conserving
therapy: Results from the EORTC boost-no boost trial (presenta-
tion). Amercian Society for Therapeutic Radiology and Oncology
(ASTRO) 49th Annual Meeting. Los Angeles, CA, 2007.
29. Morrow M, Harris JR: Practice guideline for the breast
conservation therapy in the management of invasive breast
carcinoma. JACS 2007;205:362–376.
Journal of Surgical Oncology
Residual Disease After Close Margins 103
